ANNX vs. NGNE, CRBP, ESPR, BMEA, ORGO, MRSN, HRTX, ADCT, LRMR, and RVNC
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Neurogene (NGNE), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), Biomea Fusion (BMEA), Organogenesis (ORGO), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), ADC Therapeutics (ADCT), Larimar Therapeutics (LRMR), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Neurogene (NASDAQ:NGNE) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
In the previous week, Annexon had 2 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Annexon and 4 mentions for Neurogene. Neurogene's average media sentiment score of 0.31 beat Annexon's score of -0.31 indicating that Annexon is being referred to more favorably in the news media.
Annexon's return on equity of -31.17% beat Neurogene's return on equity.
Annexon is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.
Neurogene currently has a consensus price target of $49.00, indicating a potential upside of 55.46%. Annexon has a consensus price target of $14.43, indicating a potential upside of 214.35%. Given Neurogene's higher possible upside, analysts clearly believe Annexon is more favorable than Neurogene.
Annexon received 34 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 71.93% of users gave Annexon an outperform vote.
52.4% of Neurogene shares are owned by institutional investors. 1.6% of Neurogene shares are owned by company insiders. Comparatively, 19.1% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Neurogene has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Summary
Neurogene and Annexon tied by winning 7 of the 14 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
